Using serum albumin ratios to predict sepsis outcomes
Serum Albumin Ratios Correct the Ability of Traditional Biomarkers to Predict Mortality of Sepsis Patients Admitted to Surgical ICU
This study is testing if measuring serum albumin ratios can help doctors better predict how well patients with sepsis will do in the ICU.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 12 Years to 75 Years |
| Sex | All |
| Sponsor | Benha University Academic / other |
| Locations | 1 site (Banhā, El Qalyoubia) |
| Trial ID | NCT06640504 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates how serum albumin ratios can improve the prediction of mortality and morbidity in patients with sepsis admitted to surgical ICUs. By comparing these ratios to established biomarkers like C-reactive protein, procalcitonin, and lactate, the study aims to enhance risk assessment and inform treatment strategies. The goal is to provide clinicians with a more reliable tool for identifying high-risk patients and tailoring interventions accordingly.
Who should consider this trial
Good fit: Ideal candidates are patients newly admitted to the ICU with sepsis or septic shock.
Not a fit: Patients with acute kidney injury, hemorrhagic shock, or those suspected to die in the ICU may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved survival rates and better management of sepsis in critically ill patients.
How similar studies have performed: While there have been studies exploring biomarkers in sepsis, the specific use of serum albumin ratios in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients newly admitted to ICU with sepsis or septic shock; * Patients were free of exclusion criteria. Exclusion Criteria: * Patients with acute kidney injury; * Patients with hemorrhagic shock; * Patients with immunosuppressive or autoimmune disorders; * Patients suspected to die in ICU.
Where this trial is running
Banhā, El Qalyoubia
- Benha University — Banhā, El Qalyoubia, Egypt (Recruiting)
Study contacts
- Study coordinator: Azza Mahrous Shaffik, MD
- Email: b.checked88@gmail.com
- Phone: 01062702236
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.